Stereotactic cysto-ventricular catheters in craniopharyngiomas: an effective minimally invasive method to improve visual impairment and achieve long-term cyst volume reduction

Christine Steiert1 · Juergen Grauvogel1 · Roland Roelz1 · Theo Demerath2 · Daniel Schnell3 · Juergen Beck1 · Volker Arnd Coenen4 · Peter Christoph Reinacher5

Received: 3 November 2020 / Revised: 7 February 2021 / Accepted: 22 February 2021 / Published online: 5 March 2021
© The Author(s) 2021

Abstract
Craniopharyngiomas are typically located in the sellar region and frequently contain space-occupying cysts. They usually cause visual impairment and endocrine disorders. Due to the high potential morbidity associated with radical resection, several less invasive surgical approaches have been developed. This study investigated stereotactic-guided implantation of cysto-ventricular catheters (CVC) as a new method to reduce and control cystic components. Twelve patients with cystic craniopharyngiomas were treated with CVC in our hospital between 04/2013 and 05/2017. The clinical and radiological data were retrospectively analysed to evaluate safety aspects as well as ophthalmological and endocrine symptoms. The long-term development of tumour and cyst volumes was assessed by volumetry. The median age of our patients was 69.0 years and the median follow-up period was 41.0 months. Volumetric analyses demonstrated a mean reduction of cyst volume of 64.2% after CVC implantation. At last follow-up assessment, there was a mean reduction of cyst volume of 92.0% and total tumour volume of 85.8% after completion of radiotherapy. Visual acuity improved in 90% of affected patients, and visual field defects improved in 70% of affected patients. No patient showed ophthalmological deterioration after surgery, and endocrine disorders remained stable. Stereotactic implantation of CVC proved to be a safe minimally invasive method for the long-term reduction of cystic components with improved ophthalmological symptoms. The consequential decrease of total tumour volumes optimised conditions for adjuvant radiotherapy. Given the low surgical morbidity and the effective drainage of tumour cysts, this technique should be considered for the treatment of selected cystic craniopharyngiomas.

Keywords Craniopharyngioma cyst · Minimally invasive · Stereotactic catheter · Ventriculo-cystostomy · Cysto-ventricular shunting

Introduction
Craniopharyngiomas, as rare benign extra-axial tumours, account for approximately 1–3% of all intracranial neoplasms and are frequently associated with cystic formations [6, 23]. There are two peaks in age distribution, one occurring in childhood and the other in adults between 50 and 75 years of age [23]. Due to their location in the (para-)sellar region, these tumours often lead to significant clinical impairment by compression of the optic pathways, 3rd ventricle, hypothalamus or pituitary stalk [11, 44].

Therapeutic management of craniopharyngiomas remains controversial and challenging. Complete tumour removal without neurological deterioration is difficult because of its
proximity and adherence to adjacent eloquent neural structures [11, 44]. Despite the advances in modern microsurgery, radical resection is still associated with high potential morbidity [27, 29]. Consequently, more recent therapeutic strategies aim to reduce intracranial pressure and local tumour control with improvement or preservation of visual impairment as well as the pituitary gland and hypothalamic function [14, 23, 24, 26]. Therefore, several less invasive surgical strategies to treat space-occupying cystic components have been developed, usually followed by radiotherapy [28, 36, 39].

Besides endoscopic approaches with their respective limitations due to cyst location and recurrence [12, 18, 42], appropriate minimally invasive options are stereotactic procedures like cyst punctures or catheter placement with subcutaneous Ommaya reservoirs allowing repeated cyst aspirations [39]. In these procedures, frequent cyst recurrence is a common problem but long-term reduction of cyst volume by connection to the surrounding subarachnoid space or ventricular system has been reported [9, 17, 21, 34]. The present study investigated the specific effect of stereotactic transventricular implantation of cyst catheters establishing communication between the cyst cavity and ventricular system as a minimally invasive technique to reduce and control associated cystic components in craniopharyngioma patients.

Materials and methods

Patients

Patients selected for implantation of a CVC to control cyst size fulfilled the following criteria: suprasellar tumour (histologically confirmed or radiologically defined as craniopharyngioma) with accompanying space-occupying cystic formation, need for treatment because of the mass effect and/or ophthalmologic problems, no contraindication for surgery under general anaesthesia as well as normal haemostasis and no signs of infection, informed consent of patients or a legal guardian.

Patients were treated in the Department of Functional and Stereotactic Neurosurgery in a tertiary referral centre. The retrospective analysis was approved by the independent ethics committee of our medical centre (reference no. 432/20) and is reported according to institutional guidelines.

Surgical procedure

Patients were operated under general anaesthesia. All surgeries were performed with frame-based stereotactic guidance using a Leksell G-Frame (Elekta, Stockholm, Sweden). Preoperative contrast-enhanced 3D magnetic resonance images (MRI) and intraoperative computed tomography angiography images (performed with the stereotactic frame attached to the patients’ head) were transferred to the surgical planning station (Leksell SurgiPlan®) (Elekta, Stockholm, Sweden). Surgical trajectories to the cystic components were planned transventricularly (lateral ventricles). Standard burr holes were performed under stereotactic guidance. Afterwards, a standard ventricular catheter (typically 2.8 mm diameter) stabilised by an internally located stereotactic cannula and an additional solid steel mandrin was inserted for transventricular cyst puncture under stereotactic guidance with the endpoint of the tip lying in the cyst cavity. Following Laplace’s law of fluid mechanics, permanent spontaneous drainage of cysts should be achieved via connection to the ventricular system (see Fig. 1). An x-ray control showed the catheter tip located within the endpoint. First, the mandrin was removed, and after slow aspiration of 1 ml of cyst fluid, 1 ml of contrast agent (iodine-based x-ray contrast agent Solutrast® 200 M) was carefully injected within the cavity. An x-ray control showed the cyst filled with contrast-enhanced fluid. Then, the stereotactic cannula was removed to enable free communication of the cyst cavity with the ventricular system. Another x-ray control demonstrated the
distribution of the contrast agent within the ventricular system. Afterwards, the distal end of the catheter was closed with a titanium plug (Aesculap, Tuttingen, Germany) and fixed to the skull with a titanium microfixation system (Aesculap), using one microplate (12 mm length) and two microscrews (1.5 mm diameter and 4 mm length) to prevent dislocation. Figure 2 shows the surgical steps with the corresponding intraoperative x-ray images.

In patients where a concurrent biopsy for histological confirmation was performed during CVC implantation, samples were first taken from the solid tumour using a Sedan 2.1-mm outer diameter side-cutting biopsy needle (Elekta, Stockholm, Sweden). Biopsies and CVC implantation were performed via the same trajectory, if possible, alternatively, a further non-transventricular trajectory was planned to reach the solid tumour before CVC implantation.

Outcome parameters

Three-dimensional MR imaging (3D MRI) for preoperative volumetric measurement and surgical planning was performed within 1 week before surgery. Routine postoperative MRI, performed between days 1 and 3 after surgery, documented the catheter position as well as the cyst size for postoperative volumetric analysis. Figure 3 shows the pre- and postoperative MR images with effective cyst drainage by the inserted catheter. Follow-up measurements of cyst and tumour volumes were performed using the last available follow-up MRI. Volumetric analyses based on 3D MRI were manually performed using the open-source software OsirIX (http://www.osirix-viewer.com), with average values calculated based on the measurement of each volume by two independent physicians.

Following our standard procedure, the ophthalmological status was assessed pre- and postoperatively within 1 week prior to and after surgery, respectively. To detect potential postoperative diabetes insipidus, there was frequent monitoring of fluid balance, urine specific gravity and serum electrolytes. In patients with corticotroph deficiency, the oral replacement therapy was perioperatively increased in a standard manner. In patients with intact pituitary function, hormone levels were controlled before hospital discharge.

The follow-up assessments included imaging controls as well as ophthalmological and endocrinological examinations after 3 months and every other year thereafter. Ophthalmological and endocrinological assessments were performed either by the appropriate departments in our medical centre or by specialised local physicians. The diagnostic findings were checked within annual presentations in our outpatients’ department.

Results

Patient characteristics and previous treatments

Twelve patients with histologically confirmed craniopharyngioma WHO grade I were treated with CVC in our department between 04/2013 and 05/2017 (seven male, five female). In the case of previously missing histological confirmation of craniopharyngioma, a biopsy was taken during CVC implantation. The median age at initial tumour diagnosis was 66.5 years (range 6–75 years), with a median age at treatment with CVC of 69.0 years (range 35–76 years). Detailed patient characteristics are listed in Table 1.
Due to the natural heterogeneous course of the disease, our patient population had several prior surgical interventions: one patient had an endoscopic cyst fenestration, two patients had been treated via an open surgical approach, and a previous stereotactic cyst puncture or implantation of an Ommaya system for subcutaneous cyst aspiration had been performed in nine patients prior to CVC.

**Surgery and postoperative course**

The mean duration of surgery was 46.8 min (± 10.6 min). The mean postoperative hospital stay was 4.3 days (± 1.4 days). The intraoperative course of surgeries was uneventful, with no surgery-related complications except one small asymptomatic intracerebral haemorrhage along the surgical trajectory without mass effect or treatment demand (patient no. 9). Two patients underwent stereotactic operative revision to correct the catheter position when follow-up MR imaging showed progression of the initially reduced cyst volume with dislocation of catheter tips within the cyst walls (patient nos. 1 and 2).

Three patients had been treated with external beam radiotherapy (patient nos. 4, 9 and 11) and one patient (patient no. 12) with iodine-125 brachytherapy before CVC implantation, and the others received adjuvant radiotherapy within 6 months after CVC implantation. Intensity-modulated fractionated stereotactic radiotherapy was performed in all patients (except patient no. 12) with a total radiation dose of 52.5–54.0 gray (Gy) in 30 fractions (dose per fraction: 1.75–1.8 Gy).

**Outcome**

The median clinical and radiological follow-up period was 38.5 months (± 15.3 months) and 41.0 months (± 17.1 months), respectively. Volumetric data of tumour and cyst volumes, as well as ophthalmological and endocrine parameters, were retrospectively analysed before and after surgery, and at latest follow-up.

**Volumetric outcome**

Volumetric analyses demonstrated a mean postoperative reduction of cyst volume of 64.2% compared to preoperative values. At follow-up assessments after completed radiotherapy, there was a mean reduction of cyst volume of 92.0% and total tumour volume (including solid tumour and cysts) of 85.8% compared to preoperative values, as shown graphically in Fig. 4 (patient no. 4 excluded, see below). The individual volumetric values, as well as the progression-free survival periods of each patient, are listed in Table 1. No patient in our group developed cyst regrowth or tumour progression during the follow-up period except patient no. 4. The median progression-free survival period of all patients was 41.0 months (± 17.1 months).

Patient no. 4 had been treated radiotherapeutically before CVC implantation and showed massive tumour progression with multiple new cysts in the last follow-up MRI 18 months after surgery. Due to the large solid and cystic tumour volume
| Pat. no. | Age (years) | Sex | Histological confirmation | Radiotherapy within CVC | Volumetric analysis (cm$^3$) | PFS (months) | Ophthalmological outcome |
|---------|-------------|-----|----------------------------|------------------------|-----------------------------|-------------|-------------------------|
|         |             |     |                            | Preop. postop. FU      | Preop. postop. FU           | RE          | RE LE LE LE postop. postop. |
|         |             |     |                            | Preop. postop. FU      | Preop. postop. FU           | RE          | RE LE LE LE postop. postop. |
|         |             |     |                            | Preop. postop. FU      | Preop. postop. FU           | RE          | RE LE LE LE postop. postop. |
| 1       | 75          | m   | x                          | x                      | Cyst volume                | 5.00        | 0.67 0.49 9.51 1.07 22    | 0.8 1.0 0.7 1.0 Central scotoma (BE) Stable (BE) |
| 2       | 67          | f   | x                          | x                      | Tumour volume              | 16.85       | 1.27 0.64 41.30 0.73 64 | 0.6 0.6 0.7 0.8 Incomplete bitemporal hemianopia (BE) Improved (BE) |
| 3       | 74          | f   | x                          | x                      |                            | 3.09        | 0.00 0.00 5.53 0.88 55  | 0.6 1.0 1.0 1.0 Complete left homonymous hemianopia (BE) Markedly improved on RE, improved on LE |
| 4       | 35          | m   | x                          | x                      |                            | 3.59        | 2.22 10.75 7.67 25.32 18 | 0.05* 0.05* 0.6 0.6 Complete right homonymous hemianopia (BE) + complete superior and incomplete inferior nasal quadrantanopia (RE) Markedly improved (BE) |
| 5       | 45          | f   | x                          | x                      |                            | 28.07       | 20.92 3.96 29.21 4.02 58 | 0.0* 0.0* 0.7 _** Complete left hemianopia (LE) Markedly improved (BE) |
| 6       | 71          | m   | x                          | x                      |                            | 0.59        | 0.07 0.00 2.05 0.10 41  | 0.8 0.8 0.4 0.5 Incomplete bitemporal hemianopia (BE, LE>RE) Markedly improved (BE) |
| 7       | 76          | m   | x                          | x                      |                            | 1.54        | 0.22 0.10 5.04 0.74 50  | 0.4 1.0 0.3 0.8 Complete bitemporal superior quadrantanopia (BE) Markedly improved (BE) |
| 8       | 74          | m   | x                          | x                      |                            | 6.32        | 1.45 0.94 8.87 6.68 9   | 0.2 0.3 0.5 0.7 Complete left homonymous hemianopia (BE) Stable on RE, improved on LE |
| 9       | 57          | m   | x                          | x                      |                            | 10.02       | 0.22 0.20 10.53 0.51 41 | 0.05** 0.05** 1.0 1.0 No defect No defect |
| 10      | 62          | f   | x                          | x                      |                            | 3.12        | 0.52 0.41 9.50 0.96 16  | 0.5 0.8 0.5 0.8 Incomplete bitemporal hemianopia (BE) Improved on RE, markedly improved on LE |
| 11      | 74          | f   | x                          | x                      |                            | 6.44        | 2.77 0.09 10.20 2.77 36 | 0.8 0.8 0.5 0.7 Incomplete bitemporal hemianopia (BE, LE>RE) Markedly improved (BE) |
| 12      | 35          | m   | x                          | x                      |                            | 8.16        | 3.84 0.29 15.90 2.58 42 | 1.0 1.0 1.0 1.0 No defect No defect |

*Pre-existing optic atrophy with (nearly) amaurosis on the affected eye, **pre-existing nearly amaurosis due to prior retinal detachment, ***lack of postoperative ophthalmological data
and consecutive displacement of CVC, the initially drained cyst was hard to distinguish; therefore, volumetric measurements of patient no. 4 are listed in Table 1 but were excluded from the summarised data shown in Fig. 4.

**Ophthalmological outcome**

Preoperative tumour-associated visual reduction was present in ten patients, nine of which showed improvement after surgery; patient no. 5 missed the postoperative examination, but she reported subjective improvement. Two patients without preoperative tumour-associated visual reduction remained stable without deterioration. The mean visual acuity of the right and left eyes improved after surgery from 0.48 to 0.62 and from 0.65 to 0.81, respectively.

Preoperative tumour-associated visual field defects improved in seven out of ten affected patients after surgery (two patients with full and five patients with partial recovery). Two affected patients and two non-affected patient remained stable without deterioration. No postoperative assessment of visual fields was available for patient no. 5.

The ophthalmological values of all patients are listed in Table 1.

**Endocrinological outcome**

Endocrine disorders remained stable without deterioration. Pre-existing anterior pituitary gland deficiency was present in eight patients (corticotroph axis: five patients, thyreotroph axis: seven patients, gonadotroph axis: four patients, somatotroph axis: one patient). Pre-existing posterior pituitary gland deficiency or hypothalamic disorder was present in two or three patients, respectively.

**Discussion**

For decades, the first-line therapy of craniopharyngiomas was radical surgery and gross total resection [36]. Due to the tumour invasiveness and proximity or adherence to critical neurovascular structures, H. Cushing described complete surgical removal as one of the most baffling problems faced by neurosurgeons with a high risk to produce severe secondary symptoms [8, 30]. Despite the present advancement of modern microsurgery, complete tumour removal even by expert hands still carries a relevant risk of surgery-associated damage to the visual system, as well as hypothalamic-pituitary structures with consecutive symptoms significantly lowering the quality of life [10, 22, 43]. Different strategies have been developed to address the issue of maximal local tumour control and best preserving functional integrity [29]. Subtotal resection combined with radiotherapy was established as a reasonable concept to achieve tumour control rates similar to those for gross total resection but with reduced treatment-related morbidity, hence, improved quality of life [10, 43].

Due to the heterogeneous and chronic nature of craniopharyngioma, there were several previous treatments in our group before CVC implantation, like transcranial resection, endoscopic fenestration, stereotactic puncture or implantation of Ommaya systems and prior radiotherapy. In selected cases of primarily solid craniopharyngiomas, less so in cystic tumours, fractionated stereotactic radiotherapy alone offers promising results regarding local tumour control and
functional preservation [7, 13]. Even if the solely radiotherapy-induced side effects on the visual or endocrinological system are difficult to quantify, the visual system seems to be at low risk, given the modern radiotherapeutic methods [13]. Like with any surgical intervention, endocrinological dysfunction is not about to improve, and additional endocrinopathies as well as deterioration of hypothalamic dysfunction might occur [5, 13, 41].

The vast majority of craniopharyngiomas contain cystic formations frequently leading to the compression of the surrounding neurovascular structures [6, 19, 27, 31]. Additionally, several studies have reported cyst enlargement due to radiotherapy in as many as 30–60% of craniopharyngioma patients [1, 16, 38]. Accompanying neurological deterioration requiring surgical interventions for cyst volume reduction is not uncommon [29]. Several endoscopic approaches have been described with their respective limitations, mainly due to the cyst location and the problem of cyst recurrence [12, 18, 42]. With the trend towards more conservative surgical strategies, stereotactic approaches have become increasingly important [2, 4, 10, 25, 33]. In the 1960s, Leksel et al. first developed a minimally invasive treatment concept combining stereotactic methods with ionising radiation to manage craniopharyngiomas [20]. In consideration of the high grade of accuracy and instrument stability, stereotactic approaches were later extended for other treatment options, like cyst punctures, implantation of Ommaya systems or intracystic drug injections, as well as to delay definitive surgery or radiotherapy in children for several years via consecutive cyst shrinkage [3, 40, 45]. To address the problem of cyst recurrence, intracystic catheter placement with subcutaneous reservoirs allowed repeated cyst aspirations [1, 39]. Besides causing neurological problems, fluctuating cyst sizes could also hinder radiotherapeutic treatment planning, here, stable and smallest possible conditions are preferable.

Several authors described the rather incidental finding of the long-term reduction of cyst volume by fenestration to cerebrospinal fluid (CSF) spaces [9, 17, 21, 34]. Following Laplace’s law of fluid mechanics, the fluid content of craniopharyngioma cysts, with a considerably smaller total volume compared to the cisternal or ventricular CSF system, seems to be spontaneously and permanently drained via appropriate connections. In 1989, Spaziante et al. described the phenomenon of progressive spontaneous reduction of cyst size after connecting cyst cavities to ventricular and/or cisternal CSF spaces in their series of six craniopharyngioma patients [39]. In 2013, Moussa et al. published data regarding 52 patients with mainly monocystic craniopharyngioma treated with Ommaya reservoir catheters with initial cyst aspiration. Seventy-three percent of their patients did not develop any recollection of cysts over a follow-up period of 7 years. The authors hypothesised a constant egress of cyst fluid via the terminal holes of the catheters to the subarachnoid space after the initial collapse of the cysts [21].

Following these observations, we investigated the specific effect of stereotactic transventricular implantation of CVC intending communication between the cyst cavity and ventricular system to reduce and control cystic components in craniopharyngioma patients. The minimally invasive procedure offered the advantage of a short mean duration of surgery with 46.8 min as well as a short mean postoperative hospital stay of 4.3 days. The intraoperative course was uneventful, and besides one small asymptomatic bleeding along the surgical trajectory, no further surgery-related problems occurred. Moreover, there was no additional treatment-related morbidity concerning the visual system or the endocrinological or hypothalamic function. Other authors reported similar results regarding their minimally invasive treatment methods [9, 21, 36, 39].

Problems with penetration of a possibly rough cyst capsule or secondary dislocation of the inserted catheter tip due to cyst shrinkage after initial aspiration are described for stereotactic procedures with the potential need for revision surgery [39, 46]. In our series, we also observed secondary dislocation of the catheter tip at the margin of the cyst wall after intraoperative cyst aspiration in the first two patients treated with CVC. The consecutive cyst refilling showing up on follow-up MR images led to revision surgery after several weeks. Further on, the position of the catheter tip within the cyst cavity was planned as deep as possible on the stereotactic trajectory to prevent this problem, thereby maintaining the position of the catheter even when the whole cyst content was aspirated. After this adaption, there were no further cases of catheter dislocation or cyst refilling with a correctly positioned catheter during our median follow-up period of 41 months. Catheter obstruction with debris due to the high protein content of the cyst fluid seems another possible complication, though this problem did not occur in the presented series. In these cases, further open or endoscopic surgical interventions may be required to achieve sufficient cyst fenestration.

No major complications occurred during our follow-up period; in particular, there were no cases of chemical meningitis or consecutive hydrocephalus (due to possible alterations of CSF flow or resorption rates) despite draining of cyst fluid into the CSF space. This is in line with other reports and might be attributed to the high dilution of cyst fluid in the whole CSF space [21, 36, 39]. Also, no spreading of tumour cells throughout the subarachnoid space was observed in previous publications [21, 36, 39] or in our series, which may be explained by the usual lack of tumour cells in the cyst fluid and the benign nature of the tumour.

The described method was highly efficient in the permanent reduction of the drained cysts. Volumetric analyses demonstrated a mean postoperative reduction of cyst volume of 64.2% compared to preoperative values. In our selected
patient cohort, this proved to be a stable long-term effect with a mean cyst volume reduction of 92.0% and a mean total tumour volume (including solid tumour and cysts) reduction of 85.8% at last follow-up assessments compared to preoperative values. The postoperative reduction of cyst size provided stable conditions for adjuvant radiotherapy. The long-term reduction of cyst size might be a combined effect of cystoventriculostomy and the antineoplastic radiotherapeutic effect.

Similar results with high rates of progression-free survival concerning cyst sizes are described in several case series mentioned above, in particular, in context of different strategies connecting cyst cavities to the subarachnoid space [21, 28, 32]. Rachinger et al. performed a volumetric assessment of preoperative tumour volumes, but did not report on the development of volumes in the postoperative course [34]. To our knowledge, we are the first to describe the development of cyst and tumour volumes of cystic craniopharyngiomas under stereotactic treatment with CVC. This differentiated assessment is therefore possible because in our specific patient cohort, only patients without further surgical treatments within the follow-up period were included. This allows us to make a selective statement about the safety and efficacy of the described stereotactic method.

About 75% of patients diagnosed with craniopharyngioma suffer from associated ophthalmological symptoms. In our patient group, visual impairment was improved in most patients following cyst reduction via CVC implantation in the immediate postoperative course, with no patients showing deterioration of visual status. Hence, the authors estimate high recovery rates up to 90% following tumour resection strategies and also surgery-related visual deterioration in about 15% of patients [12, 35]. Minimally invasive approaches for cyst reduction seem superior in achieving immediate visual improvement given the high rate of recovery and the near absence of new ophthalmological deficits [28, 36].

Consistent with other reports regarding minimally invasive therapeutic strategies [21, 28, 36], there was neither improvement nor deterioration of endocrinological dysfunction in our patients after CVC implantation. One of our patients suffered from a new onset of complete pituitary dysfunction 18 months after CVC implantation and adjuvant radiation therapy without new imaging aspects; therefore, this development could not be attributed to surgery. In contrast, tumour resection via the transcranial or transsphenoidal approach carries a high risk for endocrinological worsening with surgery-related new complete or incomplete pituitary dysfunction in over 50% of cases compared to minimally invasive strategies [15, 35, 37].

The ideal management of craniopharyngiomas is still controversial and challenging. Nowadays, there is a tendency away from aggressive high-risk strategies towards less invasive methods aimed at symptom relief, long-term tumour control and maintaining quality of life. The varying presentation and behaviour of these relatively rare tumours affecting a heterogeneous group of patients make it difficult to perform prospective randomised trials; thus, the publication of different therapeutic trials, even in small patient groups, seems especially important in this context giving new perspectives on patient management and the discussion of individualised treatment concepts.

Stereotactic CVC implantation proved to be a safe minimally invasive technique for the treatment of selected patients with cystic craniopharyngiomas. The risk of procedure-related complications was low and no case of deterioration of pituitary dysfunction or additional surgery-related hypophyseal or hypothalamic disorders was observed. The method was highly effective in cyst size reduction and consecutive ophthalmological improvement. Additionally, the permanent reduction of cyst size enabled enhanced and stable conditions to perform radiotherapy to further provide long-term local tumour control. Stereotactic CVC implantation seems promising in achieving acute symptom relief and long-term local tumour control with preservation or even improvement of quality of life. The small number of patients in our selected group is certainly a limitation of our study. However, this is a common problem in literature dealing with craniopharyngiomas, in particular, with the issue of minimally invasive concepts due to the rareness and heterogeneous nature of this disease.

Conclusions

Stereotactic CVC implantation proved to be a safe minimally invasive technique for the treatment of craniohypangioma cysts leading to a long-term reduction of craniohypangioma cysts with optimised conditions for radiotherapy and an improvement of visual symptoms. Combined with adjuvant radiotherapy, we consider this method as suitable for first-line therapy of cystic craniopharyngiomas, particularly in elderly patients with comorbidities impeding more invasive strategies.

Authors’ contributions All authors contributed to the study conception and design. Data collection and analysis were performed by Christine Steiert, Roland Roelz and Peter Reinacher. The first draft of the manuscript was written by Christine Steiert, Jurgen Grauvogl and Peter Reinacher and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Availability of data and material (data transparency) The anonymized datasets analyzed during the current study are available from the corresponding author on reasonable request.

Code availability (software application or custom code) Not applicable
Declarations

Ethics approval The retrospective analysis was approved by the independent ethics committee of our medical centre (reference no. 432/20) and is reported according to institutional guidelines.

Consent to participate All persons or their relatives gave their informed consent within written treatment contract on admission and therefore prior to their inclusion in the study.

Consent for publication Not applicable

Conflict of interest P.C.R. has received research support from Else Kröner-Fresenius Foundation, Fraunhofer Foundation (ATTRACT), German Ministry for Economic Affairs and Energy, and the Medical Faculty of the University of Freiburg. He has received personal honoraria for lectures or advice from Boston Scientific, Inomed, Brainlab and Fraunhofer Foundation, and is a consultant for Boston Scientific and Inomed. All other authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Al-Abayd A, El-Sheikh E (2005) Management of grossly cystic craniopharyngioma by percutaneous aspiration and external beam irradiation. Egypt J Neurosurg 21
2. Backlund EO (1972) Studies on craniopharyngiomas. I. Treatment: past and present. Acta Chir Scand 138(8):743–747
3. Backlund EO, Axellson B, Bergstrand CG, Eriksson AL, Norén G, Ribbesjö E, Råhn T, Schnell PO, Tallstedt L, Säåf M (1989) Treatment of craniopharyngiomas—their stereotactic approach in a ten to twenty-three years’ perspective. I. Surgical, radiological and ophthalmological aspects. Acta Neurochir (Wien) 99(1–2):11–19
4. Bartels U, Laperriere N, Bouffet E, Drake J (2012) Intracystic therapies for cystic craniopharyngioma in childhood. Front Endocrinol (Lausanne) 3:39
5. Bishop AJ, Greenfield B, Mahajan A, Paulino AC, Okcu MF, Allen PK, Chintagumpala M, Kahalley LS, McAleer MF, McGovern SL, Whitehead WE, Grosshans DR (2014) Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys 90(2):354–361
6. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM (1998) The descriptive epidemiology of craniopharyngioma. J Neurosurg 89(4):547–551
7. Cohen M, Bartels U, Branson H, Kulkarni AV, Hamilton J (2013) Trends in treatment and outcomes of pediatric craniopharyngioma, 1975/2011. Neuro-oncology 15(6):767–774
8. Cushing H (1932) Intracranial tumours: notes upon a series of two thousand verified cases with surgical-mortality percentages pertaining thereto. [Springfield, Ill.] ; [Baltimore, Md.] : [C.C. Thomas]
9. Ebel H, Rieber A, Spies EH, Böker DK (1995) Stereotactic cystoventricular shunting in diencephalic (arachnoid) cysts and failure in cystic craniopharyngioma. Minim Invasive Neurosurg 38(1):41–47
10. Eveslage M, Calaminus G, Warmuth-Metz M, Kortmann R-D, Pohl F, Timmermann B, Schultmann MU, Flitsch J, Faldum A, Müller HL (2019) The postoperative quality of life in children and adolescents with craniopharyngioma. Dtsch Arztebl Int 116(18):321–328
11. Fahrbusch R, Hofmann BM (2008) Surgical management of giant craniopharyngiomas. Acta Neurochir (Wien) 150(12):1213–1226
12. Fahrbusch R, Honegger J, Paulus W, Huk W, Buchfelder M (1999) Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 90(2):237–250
13. Harrabi SB, Adeberg S, Welzel T, Rieken S, Habermehl D, Debus J, Combs SE (2014) Long term results after fractionated stereotactic radiotherapy (FSRT) in patients with craniopharyngioma: maximal tumor control with minimal side effects. Radiat Oncol 9:203
14. Hoffmann A, Warmuth-Metz M, Gebhardt U, Pietsch T, Pohl F, Kortmann R-D, Calaminus G, Müller HL (2014) Childhood craniopharyngioma - changes of treatment strategies in the trials KRANIOPHARYNGEOM 2000/2007. Klin Padiatr 226(3):161–168
15. Karavitaki N, Bruflani C, Warner JT, Adams CBT, Richards P, Ansong O, Shire B, Turner HE, Wess JH (2005) Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol 62(4):397–409
16. Kornguth D, Mahajan A, Frija E, Chang E, Pelloski C, Woo S (2006) 2091: Shape variability of craniopharyngioma as measured on CT-on-Rails during radiotherapy treatment. Int J Radiat Oncol Biol Phys 66:S259–S260. https://doi.org/10.1016/j.ijrobp.2006.07.494
17. Lauretti L, Legninda Sop FY, Pallini R, Fernandez E, D’Alessandris QG (2018) Neuroendoscopic treatment of cystic craniopharyngiomas: a case series with systematic review of the literature. World Neurosurg 110:e267–e273
18. Laws ER (1980) Transsphenoidal microsurgery in the management of craniopharyngioma. J Neurosurg 52(5):661–666
19. Lee IH, Zan E, Bell WR, Burger PC, Sung H, Yousem DM (2016) Craniopharyngiomas : radiological differentiation of two types. J Korean Neurosurg Soc 59(5):466–470
20. Leksell L, Backlund EO, Johansson L (1967) Treatment of craniopharyngioma. J Neurosurg 90(2):237
21. Leksell L, Backlund EO, Johansson L (1967) Treatment of craniopharyngioma. Acta Chir Scand 133(5):345–350
22. Moussa AH, Kerasha AA, Mahmoud ME (2013) Surprising outcome of omaya reservoir in treating cystic craniopharyngioma: a retrospective study. Br J Neurosurg 27(3):370–373
23. Müller HL (2011) Consequences of craniopharyngioma surgery in children. J Clin Endocrinol Metab 96(7):1981–1991
24. Müller HL (2014) Craniopharyngioma. Endocr Rev 35(3):513–543
25. Müller HL (2016) Craniopharyngioma and hypothalamic injury: latest insights into consequent eating disorders and obesity. Curr Opin Endocrinol Diabetes Obes 23(1):81–89
26. Müller HL, Gebhardt U, Teske C, Faldum A, Zwiener I, Warmuth-Metz M, Pietsch T, Pohl F, Sörensen N, Calaminus G, Study Committee of KRANIOPHARYNGEOM 2000 (2011) Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur J Endocrinol 165(1):17–24
27. Müller HL, Merchant TE, Puget S, Martinez-Barbera JP (2017) New outlook on the diagnosis, treatment and follow-up of
childhood-onset craniopharyngioma. Nat Rev Endocrinol 13(5): 299–312

27. Müller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera J-P, Puget S (2019) Craniopharyngioma. Nat Rev Dis Primers 5(1): 75

28. Nicolato A, Foroni R, Rosta L, Gerosa M, Bricolo A (2004) Multimodality stereotactic approach to the treatment of cystic craniopharyngiomas. Minim Invasive Neurosurg 47(1): 32–40

29. Ottenhausen M, Rumalla K, La Corte E, Alalade A, Nair P, Forbes J, Ben Nsir A, Schwartz TH (2019) Treatment strategies for craniopharyngiomas. J Neurosurg Sci 63(1): 83–87

30. Pascual JM, Prieto R (2016) Harvey Cushing and pituitary Case Number 3 (Mary D.): the origin of this most baffling problem in neurosurgery. Neurosurg Focus 41(1): E6

31. Petito CK, DeGirolami U, Earle KM (1976) Craniopharyngiomas: a clinical and pathological review. Cancer 37(4): 1944–1952

32. Pollock BE, Natt N, Schomberg PJ (2002) Stereotactic management of craniopharyngiomas. Stereotact Funct Neurosurg 79(1): 25–32

33. Puget S, Garnett M, Wray A, Grill J, Habrand JL, Boddaert N, Zerah M, Bezerra M, Renier D, Pierre-Kahn A, Sainte-Rose C (2007) Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg 106(1 Suppl): 3–12

34. Rachinger W, Oehlschlaegel F, Kunz M, Fuetsch M, Schichor C, Thurai S, Schopohl J, Seelos K, Tonn J-C, Kreth F-W (2017) Cystic Craniopharyngiomas: Microsurgical or Stereotactic Treatment? Neurosurgery 80(5): 733–743

35. Radovanovic I, Dehdashti AR, Turel MK, Almeida JP, Godoy BL, Doglietto F, Vescan AD, Zadeh G, Gentili F (2019) Expanded endonasal endoscopic surgery in suprasellar craniopharyngiomas: a retrospective analysis of 43 surgeries including recurrent cases. Oper Neurosurg (Hagerstown) 17(2): 132–142

36. Rahmathulla G, Barnett GH (2013) Minimally invasive management of adult craniopharyngiomas: an analysis of our series and review of literature. Surg Neurol Int 4(Suppl 6): S411–S421

37. Sainte-Rose C, Puget S, Wray A, Zerah M, Grill J, Brauner R, Boddaert N, Pierre-Kahn A (2005) Craniopharyngioma: the pendulum of surgical management. Childs Nerv Syst 21(8–9): 691–695

38. Shi Z, Esiashvili N, Janss AJ, Mazewski CM, MacDonald TJ, Wrubel DM, Brahma B, Schwaibold FP, Marcus RB, Crocker IR, Shu HKG (2012) Transient enlargement of craniopharyngioma after radiation therapy: pattern of magnetic resonance imaging response following radiation. J Neurooncol 109(2): 349–355

39. Spaziante R, De Divitiis E, Irace C, Cappabianca P, Caputi F (1989) Management of primary or recurring grossly cystic craniopharyngiomas by means of draining systems. Topic review and 6 case reports. Acta Neurochir (Wien) 97(3–4): 95–106

40. Voges J, Sturm V, Lehrke R, Treuer H, Gauss C, Berthold F (1997) Cystic craniopharyngioma: long-term results after intracavitary irradiation with stereotactically applied colloidal beta-emitting radioactive sources. Neurosurgery 40(2): 263–269 discussion 269–270

41. Winkfield KM, Linsenmeier C, Yock TI, Grant PE, Yeap BY, Butler WE, Tarbell NJ (2009) Surveillance of craniopharyngioma cyst growth in children treated with proton radiotherapy. Int J Radiat Oncol Biol Phys 73(3): 716–721

42. Yamini B, Narayanan M (2006) Craniopharyngiomas: an update. Expert Rev Anticancer Ther 6(9s): S85–S92

43. Yang I, Sughrue ME, Rutkowski MJ, Kaur R, Ivan ME, Aranda D, Barani I, Pans A (2010) Craniopharyngioma: a comparison of tumor control with various treatment strategies. Neurosurg Focus 28(4): E5

44. Yaşargil MG, Curcic M, Kis M, Siegenthaler G, Teddy PJ, Roth P (1990) Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. J Neurosurg 73(1): 3–11

45. Zanon N, Cavalheiro S, da Silva MC (2008) Does the choice of surgical approach to insert an intratumoral catheter influence the results of intratumoral cystic treatment? Surgical Neurology 70(1): 66–69

46. Al-Abyad AG, El-Sheikh EM (2006) Management of grossly cystic craniopharyngioma by percutaneous aspiration and external beam irradiation. Egypt J Neurosurg 21: 123–37

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.